The Trump administration has finalized a rule to end federal support for gender-affirming care through Medicaid and the Children’s Health Insurance Program (CHIP), a decision that opponents say disregards medical evidence and harms vulnerable children. The rule, set to take effect on 13 October, will make it harder for young people to access essential healthcare services. Legal challenges are expected, but the policy marks a significant shift in federal healthcare funding.
What Does the Final Rule Do?
The rule explicitly prohibits Medicaid and CHIP from covering gender-affirming medical treatments, including puberty blockers, hormone therapy, and surgical interventions for minors. This applies to all states, overriding any local protections. The Department of Health and Human Services (HHS) argues the policy aligns with international reviews like the UK’s Cass Review, which critics say misrepresents evidence. However, the rule ignores a recent landmark Dutch study that found gender-affirming care is safe and effective.
Get Lifetime Access to Top AI Tools
Find Bleeding Edge Business Software at Scandalous Prices on Appsumo.
Opposition and Evidence
Advocates, including the National Women’s Law Center (NWLC), have strongly opposed the rule. During the public comment period, nearly 35,000 submissions were received, with about 90% opposing the change. Ma’ayan Anafi, senior counsel at NWLC, called the rule “incredibly dangerous” and noted that it promotes an anti-transgender agenda rather than following science. The rule also fuels state-level restrictions, creating a patchwork of care access across the country.
Comparison of Medical Reviews
| Review | Findings | Conclusion |
|---|---|---|
| Cass Review (UK) | Criticized for skewing evidence; limited long-term data | Used by HHS to justify restrictions |
| Netherlands Report | Comprehensive, recent; confirms safety and efficacy | Supports gender-affirming care widely |
Key Takeaways
- The rule ends federal funding for gender-affirming care via Medicaid and CHIP.
- It takes effect October 13, but lawsuits may delay implementation.
- Over 90% of public comments opposed the rule.
- Evidence from the Netherlands contradicts HHS’s reliance on the Cass Review.
- Advocates warn of increased stigma and harm to transgender youth.
FAQ
What is gender-affirming care?
Gender-affirming care includes medically necessary treatments like hormone therapy and puberty blockers that support a person’s gender identity. It is endorsed by major medical associations for its mental and physical health benefits.
How does this rule affect children?
Children covered by Medicaid or CHIP will lose access to gender-affirming treatments, potentially leading to worsened mental health outcomes and increased suicide risk. Families may need to seek alternative, often costly, care.
Can the rule be challenged?
Yes, legal challenges are likely. Opponents argue the rule violates constitutional rights and administrative procedures. Courts may issue injunctions to block or delay its implementation.
Best Products We’ve Tested and Rated

Our testing team has hands-on reviews of gaming headsets under, golf drivers, toddler toothbrush, shoes neuropathy, and electric tankless water heater. Every option below was compared across price, build quality, and real-world performance, with honest pros and cons. We update these guides regularly as new models arrive, so the recommendations stay current.
Our testing team has hands-on reviews of organic coffee, tankless water heater, shoes flat feet, iron clothes, and digital radio off roading. Every option below was compared across price, build quality, and real-world performance, with honest pros and cons. We update these guides regularly as new models arrive, so the recommendations stay current.